In a phase I/II study, the combination treatment was tolerable in men who had progressed on one novel anti-androgen therapy

Finding the best treatment strategy for patient subpopulations and adequate funding are key to further advancing the field, says ESMO Award 2022 recipient Prof. Karim Fizazi  

However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community

Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier  

The Pan-Asian adaptation of the ESMO guidelines introduces some changes to the standard of care in Europe, including diagnostic tests and the use of cytoreductive nephrectomy 

Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study

Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer

Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy

Early-phase studies, COSMIC-021 and CheckMate 9KD, show promising results in men with prostate cancer, but patient selection is key